» Articles » PMID: 22970693

Surveillance for Guillain-Barré Syndrome After Influenza Vaccination Among the Medicare Population, 2009-2010

Overview
Specialty Public Health
Date 2012 Sep 14
PMID 22970693
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: We implemented active surveillance for Guillain-Barré syndrome (GBS) following seasonal or H1N1 influenza vaccination among the Medicare population during the 2009-2010 influenza season.

Methods: We used weekly Medicare claims data to monitor vaccinations and subsequent hospitalizations with principal diagnosis code for GBS within 42 days. Group sequential testing assessed whether the observed GBS rate exceeded a critical limit based on the expected rate from 5 previous years adjusted for claims delay. We evaluated the lag between date of service and date of claims availability and used it for adjustment.

Results: By July 30, 2010 (after 26 interim surveillance tests), 14.0 million seasonal and 3.3 million H1N1 vaccinations had accrued. Taking into account claims delay appropriately lowered the critical limit during early monitoring. The observed GBS rate was below the critical limit throughout the surveillance.

Conclusions: Medicare data contributed rapid safety monitoring among millions of 2009-2010 influenza vaccine recipients. Adjustment for claims delay facilitates early detection of potential safety issues. Although limited by lack of medical record review to confirm cases, this claims-based surveillance did not indicate a statistically significant elevated GBS rate following seasonal or H1N1 influenza vaccination.

Citing Articles

Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older.

Wong H, Tworkoski E, Zhou C, Hu M, Thompson D, Lufkin B Vaccine. 2022; 41(2):532-539.

PMID: 36496287 PMC: 9712075. DOI: 10.1016/j.vaccine.2022.11.069.


Continuous Post-Market Sequential Safety Surveillance with Minimum Events to Signal.

Kulldorff M, Silva I Revstat Stat J. 2021; 15(3):373-394.

PMID: 34393695 PMC: 8363220.


Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season.

Perez-Vilar S, Hu M, Weintraub E, Arya D, Lufkin B, Myers T J Infect Dis. 2020; 223(3):416-425.

PMID: 33137184 PMC: 7882024. DOI: 10.1093/infdis/jiaa543.


Guillain-Barré syndrome and antecedent cytomegalovirus infection, USA 2009-2015.

Leung J, Sejvar J, Soares J, Lanzieri T Neurol Sci. 2019; 41(4):885-891.

PMID: 31828680 PMC: 7501740. DOI: 10.1007/s10072-019-04156-z.


Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review.

Mesfin Y, Cheng A, Lawrie J, Buttery J BMJ Glob Health. 2019; 4(4):e001065.

PMID: 31354969 PMC: 6615875. DOI: 10.1136/bmjgh-2018-001065.


References
1.
Smith G, Vijaykrishna D, Bahl J, Lycett S, Worobey M, Pybus O . Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009; 459(7250):1122-5. DOI: 10.1038/nature08182. View

2.
Lieu T, Kulldorff M, Davis R, Lewis E, Weintraub E, Yih K . Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007; 45(10 Supl 2):S89-95. DOI: 10.1097/MLR.0b013e3180616c0a. View

3.
. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. MMWR Morb Mortal Wkly Rep. 2010; 59(21):657-61. View

4.
Garten R, Davis C, Russell C, Shu B, Lindstrom S, Balish A . Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009; 325(5937):197-201. PMC: 3250984. DOI: 10.1126/science.1176225. View

5.
Schonberger L, Bregman D, Sullivan-Bolyai J, Keenlyside R, ZIEGLER D, Retailliau H . Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979; 110(2):105-23. DOI: 10.1093/oxfordjournals.aje.a112795. View